Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
Karen J HagerGonzalo Pérez MarcPhilipe GobeilRicardo S DiazGretchen HeizerConrado LlapurAlexander I MakarkovEduardo VasconcellosStéphane PilletFernando RieraPooja SaxenaPriscila Geller WolffKapil BhutadaGarry WallaceHessam AazamiChristine E JonesFernando P PolackLuciana FerraraJudith AtkinsIohann BoulayJiwanjeet DhaliwallNathalie CharlandManon M J CoutureJulia Jiang-WrightNathalie LandrySophie LapointeAurélien LorinAsif MahmoodLawrence H MoultonEmmy PahmerJulie ParentAnnie SéguinLuan TranThomas BreuerMaria-Angeles CeregidoMarguerite KoutsoukosFrançois RomanJunya NambaMarc-André D'AoustSonia TrepanierYosuke KimuraBrian James Wardnull nullPublished in: The New England journal of medicine (2022)
The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease. (Funded by Medicago; ClinicalTrials.gov number, NCT04636697.).